升清胶囊对豚鼠胆石病相关基因的影响.docVIP

升清胶囊对豚鼠胆石病相关基因的影响 【关键词】 ,,胆结石 ［摘要］ 目的：探讨中药升清胶囊在分子层面防治胆石病的机制。方法：雌性豚鼠60只，随机分成正常组（喂正常饮食作为对照）、模型组（喂低蛋白饮食致石）和中药组（喂低蛋白饮食致石加中药升清胶囊治疗）。6周后处死并取材，观察动物成石情况，检测肝组织胆红素尿苷二磷酸葡萄糖醛酸基转移酶（bilirubin UDPglucuronosyltransferase, BUGT）mRNA及胆固醇7α羟化酶(cholesterol 7αhydroxylase, CYP7A1)mRNA表达。结果：各组豚鼠成石比例分别为正常组2/14、模型组为9/11、中药组为4/14，组间有显著差异(P＜0.05)，正常组和中药组豚鼠的肝组织BUGT mRNA及CYP7A1 mRNA表达明显高于模型组(P＜0.05)。结论：中药升清胶囊可能是通过上调肝组织中BUGT mRNA和CYP7A1 mRNA的表达，干预胆红素和胆固醇代谢，抑制致石性胆汁形成，起到预防胆结石的作用。 ［关键词］ 胆结石; 升清胶囊; BUGT; 胆固醇7α羟化酶; 基因 Effects of Shengqing Capsules on cholelithiasisrelated genes in guinea pigs ABSTRACT Objective: To explore the molecular mechanisms of Shengqing Capsules in treating cholelithiasis. Methods: Sixty female guinea pigs were randomized into 3 groups: group Ⅰ (fed with normal diet), group Ⅱ (fed with lowprotein diet) and group Ⅲ (fed with lowprotein diet and Shengqing Capsules). After sixweek feeding, the gallstone formation and the expressions of bilirubin UDPglucuronosyltransferase (BUGT) mRNA and cholesterol 7αhydroxylase (CYP7A1) mRNA were observed. Results: The proportions of stoneformed in groups Ⅰ, Ⅱ and Ⅲ were 2/14, 9/12 and 4/14, respectively. There were significant differences among the three groups (Plt;0.05). The expressions of BUGT and CYP7A1 mRNAs were higher in both group Ⅰ and group Ⅲ as compared with those in the group Ⅱ (P＜0.05). Conclusion: Shengqing Capsules can reduce the rate of stoneformation, which may be due to its interference of metabolism of bilirubin and cholesterol and upregulation of the expressions of BUGT and CYP7A1 mRNAs. KEY WORDS cholelithiasis; Shengqing Capsules; BUGT; cholesterol 7αhdroxylase; gene 胆石病属中医“胁痛”、“黄疸”等范畴，历代医家积累了丰富的治疗经验。作者曾在已故外科专家顾伯华教授和徐长生教授采用疏肝利胆法治疗本病取得较好疗效的经验基础上，总结和开发了治疗肝胆气郁型胆石病的中成药胆宁片。近年，作者又从小复方角度进一步精简胆宁片的药味，研制开发出治疗胆石病的新一代中成药升清胶囊，并在此前的研究中发现该药能从胆石病发病的枢纽环节肝细胞水平阻断致石性病理性胆汁的形成，显著降低实验动物胆色素结石的成石率［1］。为进一步探讨升清胶囊在分子层面防治胆石病的机制，开展了以下研究。 1 材料与方法 1.1 实验材料 1.1.1 实验动物 红目雌性豚鼠，清洁级，共60只，体